N-adamantan-2-yl-4-hydroxy-benzamide | 952589-18-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-adamantan-2-yl-4-hydroxy-benzamide
• 英文别名: N-(2-adamantyl)-4-hydroxybenzamide
• CAS: 952589-18-3
• 化学式: C₁₇H₂₁NO₂
• 分子量: 271.359
• InChiKey: UZLGUXGHDYFUPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-adamantan-2-yl-4-hydroxy-benzamide 、 4-羟基环己烷甲酸乙酯 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 48.5h， 以32%的产率得到4-[4-(adamantan-2-ylcarbamoyl)-phenoxy]-cyclohexanecarboxylic acid ethyl ester
  参考文献：
  名称：

  WO2007/115935

  摘要：

  公开号：

文献信息

• 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds
  申请人：Ebdrup Soren

  公开号：US20120004209A1

  公开（公告）日：2012-01-05

  A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

  描述了一类具有通式(I)的化合物，它们在治疗中的使用、包含这些化合物的药物组合物以及它们在制药中的使用。这些化合物可以调节11β-羟基类固醇脱氢酶1型（11βHSD1）的活性，因此在治疗对此类调节有益的疾病，例如代谢综合征中有用。
• 11β-hydroxysteroid dehydrogenase type 1 active compounds
  申请人：High Point Pharmaceuticals, LLC

  公开号：US08053447B2

  公开（公告）日：2011-11-08

  A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

  本文描述了一类通式为（I）的化合物，它们在治疗中的应用，包括该化合物的制药组合物及其在药物制造中的应用。这些化合物可以调节11β-羟基类固醇脱氢酶1型（11βHSD1）的活性，因此可用于治疗需要这种调节的疾病，如代谢综合征。
• 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
  申请人：Ebdrup Soren

  公开号：US20100292215A1

  公开（公告）日：2010-11-18

  A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

  本文描述了一种新型化合物，其通式为(I)，以及它们在治疗中的应用，包括含有这些化合物的药物组合物，以及它们在制造药物方面的用途。这些化合物可以调节11β-羟基类固醇脱氢酶1型(11βHSD1)的活性，因此在治疗需要这种调节有益的疾病，例如代谢综合征方面有用。
• HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR
  申请人：McDonald Ian A.

  公开号：US20100298330A1

  公开（公告）日：2010-11-25

  The present invention is related to the preparation and pharmaceutical In use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.

  本发明涉及一种具有I式结构的新型卤代烯丙胺衍生物的制备和药物应用，所述衍生物可作为SSAO/VAP-1抑制剂，I式结构如规范中定义。本发明还涉及使用本发明化合物或其药学上可接受的盐或衍生物的方法，用于治疗多种适应症，例如炎症性疾病。
• 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
  申请人：High Point Pharmaceuticals, LLC

  公开号：EP2010479A1

  公开（公告）日：2009-01-07